IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing

Autores
Montaner, Alejandro Daniel; de Nichilo, Analía Verónica; Rodriguez, Juan Manuel; Hernando Insua, Andres; Fló, Juan; Lopez, Ricardo A.; Sierra, Verónica; PAOLAZZI, Claudio Carlos; Larghi, Oscar; Horn, David L.; Zorzopulos, Jorge; Elias, Fernanda
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Rabies virus infection causes encephalitis, which is almost always fatal. Vaccination can be extremely effective at preventing disease but is prohibitively costly. Vaccine formulations allowing dose-sparing and fewer inoculations with faster antibody response would be extremely desirable. IMT504, an immunostimulatory non-CpG oligodeoxynucleotide, is a highly potent vaccine adjuvant. Methods: Human and rat antibody measurements, and rat challenge studies were performed. Results: In rats, highly effective immune responses with IMT504 were observed even after diluting vaccine up to 1/625. In highly lethal, live intracerebral rabies challenge studies, protection occurred even with extremely dilute vaccine plus IMT504. In humans, antibody titers developed faster and were significantly higher with IMT504-adjuvanted diluted vaccine vs non-adjuvanted vaccine (full strength or diluted). All five administered IMT504- adjuvanted diluted vaccine reached protective antibodies (≥0.5 IU/ml) after the second injection. After the third injection, individuals receiving IMT504-adjuvanted diluted vaccine reached levels approximately 10 times higher than controls (M ± SEM: 31.0 ± 10.9 vs 3.40 ± 0.99 IU/ml). Conclusions: These data suggest that IMT504 may allow fewer inoculations, highly significant dose-sparing of vaccine, rapid antibody production and protection from rabies. Extensive clinical studies are necessary to confirm if the use of IMT504 will permit significantly greater access to highly effective life-saving rabies vaccines.
Fil: Montaner, Alejandro Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
Fil: de Nichilo, Analía Verónica. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
Fil: Rodriguez, Juan Manuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
Fil: Hernando Insua, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
Fil: Fló, Juan. Immunotech S.a.; Argentina
Fil: Lopez, Ricardo A.. Immunotech S.a.; Argentina
Fil: Sierra, Verónica. Instituto San Jorge Bagó; Argentina
Fil: PAOLAZZI, Claudio Carlos. Instituto San Jorge Bagó; Argentina
Fil: Larghi, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
Fil: Horn, David L.. David Horn; Estados Unidos
Fil: Zorzopulos, Jorge. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Immunotech S.a.; Argentina
Fil: Elias, Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
Materia
IMT504
Adjuvant
Rabies
Vaccine
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/67890
Acceder
id CONICETDig_849c02a7739caa533a68384d2e556932
oai_identifier_str oai:ri.conicet.gov.ar:11336/67890
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose SparingMontaner, Alejandro Danielde Nichilo, Analía VerónicaRodriguez, Juan ManuelHernando Insua, AndresFló, JuanLopez, Ricardo A.Sierra, VerónicaPAOLAZZI, Claudio CarlosLarghi, OscarHorn, David L.Zorzopulos, JorgeElias, FernandaIMT504AdjuvantRabiesVaccinehttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background: Rabies virus infection causes encephalitis, which is almost always fatal. Vaccination can be extremely effective at preventing disease but is prohibitively costly. Vaccine formulations allowing dose-sparing and fewer inoculations with faster antibody response would be extremely desirable. IMT504, an immunostimulatory non-CpG oligodeoxynucleotide, is a highly potent vaccine adjuvant. Methods: Human and rat antibody measurements, and rat challenge studies were performed. Results: In rats, highly effective immune responses with IMT504 were observed even after diluting vaccine up to 1/625. In highly lethal, live intracerebral rabies challenge studies, protection occurred even with extremely dilute vaccine plus IMT504. In humans, antibody titers developed faster and were significantly higher with IMT504-adjuvanted diluted vaccine vs non-adjuvanted vaccine (full strength or diluted). All five administered IMT504- adjuvanted diluted vaccine reached protective antibodies (≥0.5 IU/ml) after the second injection. After the third injection, individuals receiving IMT504-adjuvanted diluted vaccine reached levels approximately 10 times higher than controls (M ± SEM: 31.0 ± 10.9 vs 3.40 ± 0.99 IU/ml). Conclusions: These data suggest that IMT504 may allow fewer inoculations, highly significant dose-sparing of vaccine, rapid antibody production and protection from rabies. Extensive clinical studies are necessary to confirm if the use of IMT504 will permit significantly greater access to highly effective life-saving rabies vaccines.Fil: Montaner, Alejandro Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; ArgentinaFil: de Nichilo, Analía Verónica. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; ArgentinaFil: Rodriguez, Juan Manuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; ArgentinaFil: Hernando Insua, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; ArgentinaFil: Fló, Juan. Immunotech S.a.; ArgentinaFil: Lopez, Ricardo A.. Immunotech S.a.; ArgentinaFil: Sierra, Verónica. Instituto San Jorge Bagó; ArgentinaFil: PAOLAZZI, Claudio Carlos. Instituto San Jorge Bagó; ArgentinaFil: Larghi, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; ArgentinaFil: Horn, David L.. David Horn; Estados UnidosFil: Zorzopulos, Jorge. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Immunotech S.a.; ArgentinaFil: Elias, Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; ArgentinaScientific Research Publishing Inc2012-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/67890Montaner, Alejandro Daniel; de Nichilo, Analía Verónica; Rodriguez, Juan Manuel; Hernando Insua, Andres; Fló, Juan; et al.; IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing; Scientific Research Publishing Inc; World Journal of Vaccines; 02; 04; 11-2012; 182-1882160-5823CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://file.scirp.org/Html/2-5100063_24805.htminfo:eu-repo/semantics/altIdentifier/doi/10.4236/wjv.2012.24025info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:10:52Zoai:ri.conicet.gov.ar:11336/67890instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:10:52.883CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing
title IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing
spellingShingle IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing
Montaner, Alejandro Daniel
IMT504
Adjuvant
Rabies
Vaccine
title_short IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing
title_full IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing
title_fullStr IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing
title_full_unstemmed IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing
title_sort IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing
dc.creator.none.fl_str_mv Montaner, Alejandro Daniel
de Nichilo, Analía Verónica
Rodriguez, Juan Manuel
Hernando Insua, Andres
Fló, Juan
Lopez, Ricardo A.
Sierra, Verónica
PAOLAZZI, Claudio Carlos
Larghi, Oscar
Horn, David L.
Zorzopulos, Jorge
Elias, Fernanda
author Montaner, Alejandro Daniel
author_facet Montaner, Alejandro Daniel
de Nichilo, Analía Verónica
Rodriguez, Juan Manuel
Hernando Insua, Andres
Fló, Juan
Lopez, Ricardo A.
Sierra, Verónica
PAOLAZZI, Claudio Carlos
Larghi, Oscar
Horn, David L.
Zorzopulos, Jorge
Elias, Fernanda
author_role author
author2 de Nichilo, Analía Verónica
Rodriguez, Juan Manuel
Hernando Insua, Andres
Fló, Juan
Lopez, Ricardo A.
Sierra, Verónica
PAOLAZZI, Claudio Carlos
Larghi, Oscar
Horn, David L.
Zorzopulos, Jorge
Elias, Fernanda
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv IMT504
Adjuvant
Rabies
Vaccine
topic IMT504
Adjuvant
Rabies
Vaccine
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Rabies virus infection causes encephalitis, which is almost always fatal. Vaccination can be extremely effective at preventing disease but is prohibitively costly. Vaccine formulations allowing dose-sparing and fewer inoculations with faster antibody response would be extremely desirable. IMT504, an immunostimulatory non-CpG oligodeoxynucleotide, is a highly potent vaccine adjuvant. Methods: Human and rat antibody measurements, and rat challenge studies were performed. Results: In rats, highly effective immune responses with IMT504 were observed even after diluting vaccine up to 1/625. In highly lethal, live intracerebral rabies challenge studies, protection occurred even with extremely dilute vaccine plus IMT504. In humans, antibody titers developed faster and were significantly higher with IMT504-adjuvanted diluted vaccine vs non-adjuvanted vaccine (full strength or diluted). All five administered IMT504- adjuvanted diluted vaccine reached protective antibodies (≥0.5 IU/ml) after the second injection. After the third injection, individuals receiving IMT504-adjuvanted diluted vaccine reached levels approximately 10 times higher than controls (M ± SEM: 31.0 ± 10.9 vs 3.40 ± 0.99 IU/ml). Conclusions: These data suggest that IMT504 may allow fewer inoculations, highly significant dose-sparing of vaccine, rapid antibody production and protection from rabies. Extensive clinical studies are necessary to confirm if the use of IMT504 will permit significantly greater access to highly effective life-saving rabies vaccines.
Fil: Montaner, Alejandro Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
Fil: de Nichilo, Analía Verónica. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
Fil: Rodriguez, Juan Manuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
Fil: Hernando Insua, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
Fil: Fló, Juan. Immunotech S.a.; Argentina
Fil: Lopez, Ricardo A.. Immunotech S.a.; Argentina
Fil: Sierra, Verónica. Instituto San Jorge Bagó; Argentina
Fil: PAOLAZZI, Claudio Carlos. Instituto San Jorge Bagó; Argentina
Fil: Larghi, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
Fil: Horn, David L.. David Horn; Estados Unidos
Fil: Zorzopulos, Jorge. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Immunotech S.a.; Argentina
Fil: Elias, Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología ; Argentina
description Background: Rabies virus infection causes encephalitis, which is almost always fatal. Vaccination can be extremely effective at preventing disease but is prohibitively costly. Vaccine formulations allowing dose-sparing and fewer inoculations with faster antibody response would be extremely desirable. IMT504, an immunostimulatory non-CpG oligodeoxynucleotide, is a highly potent vaccine adjuvant. Methods: Human and rat antibody measurements, and rat challenge studies were performed. Results: In rats, highly effective immune responses with IMT504 were observed even after diluting vaccine up to 1/625. In highly lethal, live intracerebral rabies challenge studies, protection occurred even with extremely dilute vaccine plus IMT504. In humans, antibody titers developed faster and were significantly higher with IMT504-adjuvanted diluted vaccine vs non-adjuvanted vaccine (full strength or diluted). All five administered IMT504- adjuvanted diluted vaccine reached protective antibodies (≥0.5 IU/ml) after the second injection. After the third injection, individuals receiving IMT504-adjuvanted diluted vaccine reached levels approximately 10 times higher than controls (M ± SEM: 31.0 ± 10.9 vs 3.40 ± 0.99 IU/ml). Conclusions: These data suggest that IMT504 may allow fewer inoculations, highly significant dose-sparing of vaccine, rapid antibody production and protection from rabies. Extensive clinical studies are necessary to confirm if the use of IMT504 will permit significantly greater access to highly effective life-saving rabies vaccines.
publishDate 2012
dc.date.none.fl_str_mv 2012-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/67890
Montaner, Alejandro Daniel; de Nichilo, Analía Verónica; Rodriguez, Juan Manuel; Hernando Insua, Andres; Fló, Juan; et al.; IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing; Scientific Research Publishing Inc; World Journal of Vaccines; 02; 04; 11-2012; 182-188
2160-5823
CONICET Digital
CONICET
url http://hdl.handle.net/11336/67890
identifier_str_mv Montaner, Alejandro Daniel; de Nichilo, Analía Verónica; Rodriguez, Juan Manuel; Hernando Insua, Andres; Fló, Juan; et al.; IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing; Scientific Research Publishing Inc; World Journal of Vaccines; 02; 04; 11-2012; 182-188
2160-5823
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://file.scirp.org/Html/2-5100063_24805.htm
info:eu-repo/semantics/altIdentifier/doi/10.4236/wjv.2012.24025
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Scientific Research Publishing Inc
publisher.none.fl_str_mv Scientific Research Publishing Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842270135883137024
score 13.13397

Publicaciones similares